VENESSA COAKE: Open Payments
NPI 1952701336 · BLACKSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$920 in 47 payments from 18 companies in 2025. Trend: 2023 $948 · 2024 $354 · 2025 $920
Food & beverage: $920
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $194 |
| Lundbeck LLC | 6 | $131 |
| Lilly USA, LLC | 5 | $99 |
| ABBVIE INC. | 5 | $82 |
| Novo Nordisk Inc | 4 | $69 |
| Neurocrine BioSciences, Inc. | 2 | $50 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
Products named: CAPLYTA, REXULTI, MOUNJARO, VRAYLAR, INGREZZA, VOQUEZNA, XIFAXAN, Ozempic.
Industry payments across VA — which companies pay providers there.
